Pharmaceuticals

RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland

TEL AVIV, Israel and RALEIGH, N.C., March 22, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib[1] treatment on an...

2021-03-22 19:00 3021

Everest Medicines Announces Acceptance of New Drug Application by China NMPA for Xerava(TM) for the Treatment of Complicated Intra-abdominal Infections

SHANGHAI, March 22, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater ...

2021-03-22 10:40 3175

Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China

SHANGHAI and SUZHOU, China, March 22, 2021 /PRNewswire/ -- Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the first patient in its open Phase I clinical study of HBM4003 for Chinese patients suffering from advanced melanoma and other solid tumors (study No. 4003.2). This study w...

2021-03-22 10:31 4195

Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021

SHANGHAI and GAITHERSBURG, Md., March 22, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in hematolog...

2021-03-22 08:00 2500

Innoforce Pharmaceuticals Completes 625M CNY ($96M) Series A Financing

HANGZHOU, China, March 22, 2021 /PRNewswire/ -- Innoforce Pharmaceuticals ("INF"), a biopharmaceutical innovation and partnership company, announced today the completion of a625M CNY ($96M) Series A financing, which follows a 170M CNY ($24M) Pre-A financing completed in June 2020. The Series A ...

2021-03-22 08:00 3768

Ocumension Therapeutics (1477.HK) Reports Revenue Growth in 2020, National Commercial Construction has been started to become outstanding

HONG KONG, March 20, 2021 /PRNewswire/ -- The Chinese ophthalmology platform company,Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, the "Group" ), (stock code: 1477.HK), announced its annual results for the year ended31 December 2020 today. Ocumension The...

2021-03-20 18:20 8477

Qiming's Portfolio Company Connect Biopharma Lists on Nasdaq

SHANGHAI, March 20, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company Connect Biopharma today listed on the Nasdaq with the stock code "CNTB". The issue price isUS$ 17.00/ADS. The stock opened at US$19.55/ADS and closed atUS$18.49/ADS on the first trading day, up 8.8%, with a market...

2021-03-20 09:00 15227

Everest Medicines to Announce Full-Year 2020 Financial Results on March 22, 2021

SHANGHAI, March 19, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater China and other parts of Asia, today announced ...

2021-03-19 14:43 4237

WuXi Biologics to Acquire CMAB and Form Strategic Partnership with CBC Group

SUZHOU, China, March 18, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced it has entered into a purchase agreement with CBC Group ("CBC"), a healthcare-dedicated investment firm, and other compani...

2021-03-18 08:59 2865

Merck Accelerates European Expansion Plans for Single-use Products Critical to Manufacturing Vaccines and Lifesaving Therapies

DARMSTADT, Germany, March 17, 2021 /PRNewswire/ -- Merck, a leading science and technology company, will add a single-use assembly production unit at its Life Science Center in Molsheim,France. With the € 25 million investment, the company is accelerating its European expansion plans for this key...

2021-03-17 23:40 2658

WuXi Biologics to Acquire Biologics DS and DP Manufacturing Facilities from Pfizer China

HANGZHOU, China, March 17, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has entered into an equity agreement with Pfizer China ("Pfizer") to acquire its state-of-the-art biologics manu...

2021-03-17 08:45 2591

WuXi Vaccines Achieves Weather-Tight Construction Milestone on Main Building of Manufacturing Facility Despite COVID-19

SHANGHAI and DUNDALK, Ireland, March 16, 2021 /PRNewswire/ -- WuXi Vaccines, a world-leading vaccine Contract Development and Manufacturing Organization (CDMO), today announced it achieved the weather-tight construction milestone of its vaccine manufacturing facility currently under construction ...

2021-03-16 16:30 2366

Merck Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer

Not intended for US-, Canada- or UK-based media DARMSTADT, Germany, March 16, 2021 /PRNewswire/ -- Merck, a leading science and technology company, today announced topline data from the Phase II INTR@PID BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment of ...

2021-03-16 15:00 2662

Sihuan Pharmaceutical (0460.HK): 'A Friend of Time' 2021 - The Turning-point Year

HONG KONG, March 16, 2021 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. plays a pivotal role in China's domestic medical industry and is a leading company for the development of the country's cardio-cerebral vascular prescription drugs. According to IMS data in 2018, Sihuan Pharmaceut...

2021-03-16 14:48 3254

QBiotics Welcomes TDM Growth Partners As Cornerstone Investor in a Capital Raise To Accelerate Drug Development Timelines

Key highlights: * QBiotics welcomes TDM Growth Partners as cornerstone investor * TDM Growth Partners is investing A$50 million into QBiotics to accelerate QBiotics' human drug development pipeline, support marketing of the company's veterinary pharmaceutical STELFONTA® and strengthen the QBi...

2021-03-16 06:35 2401

CBC Group Announces the Appointment of Roger Perlmutter as Science Partner

SHANGHAI, March 15, 2021 /PRNewswire/ -- CBC Group ("CBC"), a healthcare-dedicated investment firm, is pleased to announce that Roger M. Perlmutter, M.D., Ph.D., currently non-Executive Chairman, Merck Research Laboratories, joins CBC as Science Partner and a member of its Scientific Advisory Bo...

2021-03-15 22:00 2483

Antengene Included in the Shenzhen-Hong Kong Stock Connect

SHANGHAI and HONG KONG, March 14, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and o...

2021-03-15 09:40 2933

Antengene Appoints Minyoung Kim as General Manager of Antengene South Korea

SHANGHAI and SEOUL, South Korea, March 15, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in hematolo...

2021-03-15 08:00 3298

SuperTrans Medical appoints Australian partners to provide crucial clinical research in the battle against drug-resistant bacteria

MELBOURNE, Australia, March 15, 2021 /PRNewswire/ -- SuperTrans Medical has announced the appointment of three Australian companies to play pivotal roles in an upcoming clinical drug trial that offers new hope in the plight against antimicrobial resistance (AMR), which the World Health Organisati...

2021-03-15 07:08 1535

Cardinal Health signs definitive agreement to sell its Cordis business to Hellman & Friedman

DUBLIN, Ohio, March 12, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced that it has signed a definitive agreement to sell its Cordis business to Hellman & Friedman (H&F) for approximately$1 billion, which includes buyer's assumption of certain liabilities and seller's retention o...

2021-03-12 22:00 8331
1 ... 124125126127128129130 ... 181